Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pyridostatin TFA 是一种 G-四链体稳定剂,靶向原癌基因 Src,降低人乳腺癌细胞 SRC 蛋白水平和 SRC 依赖的细胞运动。它通过诱导复制和转录依赖的 DNA 损伤促进人类癌细胞生长停滞。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 285 | 现货 | ||
2 mg | ¥ 397 | 现货 | ||
5 mg | ¥ 669 | 现货 | ||
10 mg | ¥ 987 | 现货 | ||
25 mg | ¥ 1,950 | 现货 | ||
50 mg | ¥ 2,960 | 现货 | ||
100 mg | ¥ 4,370 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 877 | 现货 |
产品描述 | Pyridostatin Trifluoroacetate Salt is a G-quadruplexe stabilizer with Kd of 490 nM in a cell-free assay, which targets a series of proto-oncogenes including c-kit, K-ras and Bcl-2. |
靶点活性 | G-quadruplexe (Cell-free assay):490 nM(Kd) |
体外活性 | Pyridostatin decreases the proliferation of MRC-5–SV40 cells and various cancer cell lines, and induces cell-cycle arrest by DNA-damage checkpoint activation. Pyridostatin also reduces SRC-dependent cell motility in MDA-MB-231 cells by interacting with G-quadruplex motifs in SRC.Pyridostatin decreases EBNA1 synthesis via inhibition of G-quadruplexes. |
细胞实验 | Cell lines: MRC-5–SV40 cells and various cancer cell linesConcentrations: 10 μMIncubation Time: 48 hMethod: Cells are plated at equal confluence and are left either untreated or were treated with 2 μM pyridostatin continually during the indicated time before harvesting the cells. Cells from individual plates are trypsinized and counted in a Coulter counter. Graphs represent the total cell numbers at each time interval, and the error bars represent the s.e.m. Data represent three independent experiments. |
分子量 | 938.71 |
分子式 | C37H35F9N8O11 |
CAS No. | 1472611-44-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (95.88 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.0653 mL | 5.3265 mL | 10.6529 mL | 26.6323 mL |
5 mM | 0.2131 mL | 1.0653 mL | 2.1306 mL | 5.3265 mL | |
10 mM | 0.1065 mL | 0.5326 mL | 1.0653 mL | 2.6632 mL | |
20 mM | 0.0533 mL | 0.2663 mL | 0.5326 mL | 1.3316 mL | |
50 mM | 0.0213 mL | 0.1065 mL | 0.2131 mL | 0.5326 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Pyridostatin TFA 1472611-44-1 Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis RR82 neurodegeneration G-quadruplex SRC inhibit arrest damage cycle DSB Pyridostatin RR-82 Inhibitor RR 82 DNA structure inhibitor